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 Cardiovascular disease is a leading cause of death worldwide. Since adult cardiac cells are lim-
ited in their proliferation, cardiac tissue with dead or damaged cardiac cells downstream of 
the occluded vessel does not regenerate after myocardial infarction. The cardiac tissue is then 
replaced with nonfunctional fi brotic scar tissue rather than new cardiac cells, which leaves the 
heart weak. The limited proliferation ability of host cardiac cells has motivated investigators to 
research the potential cardiac regenerative ability of stem cells. Considerable progress has been 
made in this endeavor. However, the optimum type of stem cells along with the most suitable 
matrix-material and cellular microenvironmental cues are yet to be identifi ed or agreed upon. 
This review presents an overview of various types of biofunctional materials and biomaterial 
matrices, which in combination with stem cells, have shown 
promises for cardiac tissue replacement and reinforcement. 
Engineered biomaterials also have applications in cardiac 
tissue engineering, in which tissue constructs are developed 
in vitro by combining stem cells and biomaterial scaffolds for 
drug screening or eventual implantation. This review high-
lights the benefi ts of using biomaterials in conjunction with 
stem cells to repair damaged myocardium and give a brief 
description of the properties of these biomaterials that make 
them such valuable tools to the fi eld. 
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 1.  Introduction 
 Myocardial infarction (MI) is one of the main causes of 
morbidity and mortality around the world. [ 1 ] Each year 
around one million deaths occur due to heart failure in 
the United States alone. [ 2 ] MI results from the obstruc-
tion of cardiac vessels which halts blood fl ow to part of 
the heart causing damage to that portion of the myo-
cardium. Blood fl ow can be restored in the occluded tis-
sues by balloon angioplasty, stenting, and cardiac bypass 
surgeries; however, the damaged cardiac tissue does not 
self-regenerate and the heart remains weak. Recent devel-
opments in stem cell research aim to restore injured myo-
cardium by regenerative medicine and tissue engineering 
methods. 
 Adult cardiomyocytes are terminally differentiated 
cells that have a minimal proliferation capacity and that 
cannot be extracted in suffi cient numbers. A potential 
alternative to cardiomyocytes for cardiac repair is stem 
cells—a self-renewable and differentiable cell source 
that has provoked increased cardiac function following 
cell-based therapy. [ 3 ] Some types of stem cells, such as 
mesenchymal stem cells (MSCs) and cardiac stem cells 
(CSCs), have made it to human trials. Recently, atten-
tion has turned toward the potential therapeutic effects 
of partially differentiated stem cells such as adipose-
derived adult stem cells and endothelial progenitor 
cells. Endothelial progenitor cells were shown to directly 
trigger pro-angiogenic factors and healing responses 
that may be of potential use for tissue engineering and 
regenerative medicine. Embryonic stem cells (ESCs) are 
another source of stem cells that have engendered propi-
tious results in cardiac regeneration. ESCs are pluripotent, 
are easily handled and proliferated, and were shown to 
differentiate into cardiomyocytes. [ 4 ] Animal studies have 
demonstrated some repairs in damaged heart muscle 
using this cell line. Despite positive results from ESCs, 
numerous ethical controversies have driven research 
away from them. A solution to these concerns may be 
found in somatic cells that have been “reprogrammed” 
and found to mimic ESCs engineered induced pluripotent 
stem cells (iPSCs). [ 5 ] They are among the most recent ESC 
alternative sources under investigation in animal models. 
More effective cardiac therapy for any of the above stem 
cells has been achieved through the careful regulation of 
stem cell environment in conjunction with the addition 
of growth factors and chemokines. 
 Regenerative medicine and tissue engineering tech-
niques are at the center of the most promising “next-
generation” therapies for MI. [ 3 ] Regenerative medicine 
is intended to repair the damaged cardiac tissue in 
vivo by injecting cells directly into the heart. Several 
delivery routes have been proposed, such as intracoro-
nary, intravenous, intramyocardial, retrograde sinus, and 
intrapericardial routes. None of the stem cell delivery 
routes has yet been proclaimed to be superior to the 
others and each one has individually shown some advan-
tages. A vehicle that scientists have used in order to 
increase the effi cacy of stem cell injections in regenera-
tive medicine is injectable hydrogels. Alternatively, tissue 
engineering combines expertise in cell biology, engi-
neering, and materials in order to grow a cardiac tissue 
in vitro. This tissue construct is engineered to mimic the 
behavior of human heart tissue and is later transplanted 
into a patient’s heart to improve or replace nonfunctional 
cells. Undifferentiated stem cells placed within cardiac 
constructs have been tested in MI animal models and 
have shown to improve survival rate, decrease the area 
of the damaged myocardium, and increase overall car-
diac function. In these instances, stem cells differentiated 
into cardiomyocytes in vivo, and thus the differentiation 
process was uncontrolled and sometimes resulted in the 
development of teratomas. In further studies, scientists 
have differentiated stem cells in vitro prior to implanta-
tion of the cardiac construct, which offered improved 
results. Among the most successful methodologies in 
tissue engineering are the use of cell sheets and porous 
scaffolds. While neither regenerative medicine nor tissue 
engineering methods are suffi cient as independent solu-
tions for cardiac cell repair following MI, these approaches 
are advancing fast which demonstrates a strong potential 
for a stand-alone solution. 
 Recent advances are looking toward the refi nement of 
current techniques and the minimization of complica-
tions. For example, the differentiation of stem cells into 
the right cell lineage as well as the preservation of the 
genetic footprint are sometimes problematic and can 
be hindered by the development of teratomas. [ 6 ] Inves-
tigations have revealed that the source of stem cells is 
an important factor that affects cell differentiation. In 
addition, only a few of biomaterials used in regenerative 
medicine and tissue engineering have made it to human 
trials and improvements are necessary in terms of their 
mechanical, biological, and physical properties to provide 
optimal conditions for stem cell growth, differentiation, 
and retention. [ 7 ] 
 2.  Stem Cells to Heal Damaged Heart 
 Stem cells are undifferentiated cells that exist in various 
regions of the body and have two main roles. The fi rst is 
growth for embryos and tissue maintenance and the 
second is regeneration and repair for adults. [ 3 ] There are 
several properties that stem cell types must exhibit in order 
to be selected as candidates for cardiac therapy. Primarily, 
they should be able to increase heart function by differ-
entiating into cardiomyocytes when placed in a suitable 
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environment and/or through indirect paracrine effects. 
The ability of stem cells to differentiate depends on their 
potency: pluripotent, multipotent, totipotent, or unipo-
tent. The environment in which stem cells are cultured or 
delivered can facilitate the process of their differentiation 
into cardiomyocytes. Second, the cells must be relatively 
easy to isolate and maintain, and they should also have 
the ability to proliferate in suffi cient numbers. In addi-
tion, they should be able to survive harvesting, delivery 
and the harsh microenvironment of the infarcted myo-
cardium. Finally, stem cells should cause a low immuno-
genic response lest the benefi ts of the cells be completely 
annulled by the damage of an immunological response. [ 8 ] 
 Since cardiac tissue engineering and regenerative 
medicine requires a large quantity of cells, terminally 
differentiated adult cardiomyocytes which have a low 
proliferative capacity are unsuitable for these applica-
tions. Stem cells, on the other hand, can appropriately 
differentiate into cardiomyocytes and proliferate enough 
to meet the quantity requirements. Due to the relatively 
easy accessibility of resident stem cells, an ideal method 
would be to use cardiac-like cells derived from this type 
of stem cell. [ 9 ] The types of stem cells that have been used 
widely in animal models for cardiac repair are embryonic 
stem cells, induced pluripotent stem cells and stem cells 
from various adult tissues. [ 10 ] 
 2.1.  Types of Stem Cells 
 ESCs fulfi ll most of the requirements for stem cell based 
cardiac therapy including clonality, self-renewal and 
pluripotency. [ 3,10 ] ESCs have shown a clear ability to dif-
ferentiate into functional cardiomyocytes and endothelial 
cells, therefore, they have the potential to reproduce sev-
eral elements of damaged heart. [ 8 ] Cardiomyocytes derived 
from human ESCs have been tested on animal models 
and have been shown to survive after their transplanta-
tion, partly remodel the infarcted area, and positively 
improve contractile function. [ 11 ] Recently, researchers have 
been able to “reprogram” somatic cells to get them to an 
ES cell-like state by transduction of defi ned transcription 
factors. [ 3,12 ] These “engineered” ESCs called iPSCs have 
been shown to differentiate into functional cardiomyo-
cytes. [ 13,14 ] The iPSCs present an appropriate alternative to 
human ESCs by surpassing ESCs ethical concerns and pro-
viding an ideal autologous cell source, which reduces the 
chances of an immunological response. [ 5,15 ] Also, the use 
of iPSCs bypasses the need for invasive surgery because of 
the wide availability and accessibility of cells eligible for 
suitable reprogramming. [ 16 ] Although iPSCs have not yet 
reached a human trials phase, they have shown promising 
survival results in the infarcted myocardium and marginal 
renewal of heart function in animal models that are com-
parable to other cell sources. However, much work remains 
to be done in order to enhance their engraftment, survival 
rate, and therapeutic effi ciency. [ 16 ] 
 Adult stem cells are another option that scientists have 
extensively studied. These cells are in several locations 
throughout the human body. [ 17 ] For cardiac purposes, sci-
entists have used cells from several sources such as the 
heart, bone marrow, umbilical cord, placenta, and adi-
pose tissue. For example, hematopoietic stem cells can be 
found in umbilical cords, placenta, and bone marrow. [ 3 ] 
MSCs can be harvested from femoral heads, endome-
trium, bone marrow and adipose tissue. [ 18 ] Due to their 
ease of accessibility through noninvasive surgery and 
their low immunogenicity, MSCs are good candidates for 
allogeneic stem cell therapies. In addition, they have a 
high proliferative potential and can be grown extensively 
in vitro, making them an attractive option for scien-
tists. [ 17 ] Many studies on animal models have shown that 
the injection of MSCs is benefi cial in the case of cardiac 
injuries and diseases. [ 19 ] The cells have been shown to 
differentiate into beating heart cells in vitro, to increase 
vascularization density when transplanted into ischemic 
murine model, and to prevent scar expansion. [ 20,21 ] MSC 
human therapy trials have recently started with initial 
success. [ 22 ] Among the different origins of MSCs, adipose-
derived stem cells (ASCs) have shown great promise for an 
autologous source due to their large availability and rela-
tive ease of isolation through liposuction. [ 3,19 ] Around a 
decade ago, CSCs were found in the heart using negative 
c-kit, [ 23 ] Sca-1, [ 24 ] isl1 [ 25 ] and cardiosphere-forming cells [ 26 ] 
stem cell markers. Since then, scientists have investi-
gated their use in regenerative medicine using methods 
such as cardiosphere-forming technology to isolate CSCs 
from heart tissue. One example is the SCIPIO human 
trial that is being conducted with autologous c-kit+ CSCs 
for the treatment of MI. Results have revealed that the 
intracoronary delivery of these cells is safe, improves LV 
systolic function and reduces the size of the ischemic 
tissue. However, surviving and engrafted cells are low in 
number. [ 27,28 ] Along with CSCs, another important adult 
cell type that needs to be considered is endothelial pro-
genitor cells (EPCs). These cells are defi ned as circulating 
cells that express a variety of cell surface markers similar 
to those expressed by vascular endothelial cells, adhere 
to endothelium at sites of hypoxia/ischemia, mediate 
tissue-protective effects, and participate in new vessel 
formation. [ 29 ] In an experimentally induced MI, neoangio-
genesis triggered by EPCs resulted in decreased apoptosis 
of hypertrophic myocytes in the peri-infarct region, long-
term salvage and survival of viable myocardium, reduc-
tion in collagen deposition, and sustained improvement 
in cardiac function. [ 30 ] 
 Each of the sources of cells previously mentioned have 
their own drawbacks that scientists are striving to over-
come. CSCs and EPCs do not pose an ideal solution due 
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to their scarcity. [ 31 ] Isolation of adult stem cells remains 
a problem since it usually results in a heterogeneous 
population of cells, which requires the use of cell surface 
markers to isolate the required stem cell types. The use 
of ESCs is signifi cantly hindered by ethical issues as well 
as risks of teratoma formation. [ 12,32 ] Also, more research 
needs to be conducted to study iPSC behavior in order to 
minimize the possibility of teratoma formation and opti-
mize therapeutic benefi t in damaged myocardium. Scien-
tists are working hard to resolve these issues to determine 
the ideal source for cardiac tissue engineering and regen-
erative medicine. Many studies are being conducted to 
better defi ne the intrinsic nature of the adult stem cell 
types mentioned above as well as the mechanism behind 
some of the noted differentiation, transdifferentiation 
and engraftment contributing to the improvement of car-
diac function. Despite the fact that stem cell grafting and 
retention has remained low, results look promising. 
 2.2.  Regenerative Medicine Cell Delivery Routes 
 Regenerative medicine induces myocardial repair at the 
site of injury in vivo and prevents ventricular dilatation 
after MI through an injection of stem cells. Successful 
delivery is crucial for an ideal stem cell therapy into the 
cardiac tissue. There are fi ve main delivery routes: intracor-
onary, intravenous, intramyocardial, retrograde sinus and 
intrapericardial. [ 33 ] The intracoronary infusion technique 
involves cell fusion through the central lumen of a balloon 
catheter positioned in the coronary artery. [ 34 ] This route 
limits risks of systemic administration, as the delivery con-
centration is higher in ischemic and border zone regions. 
It is generally used for patients who have electrocardio-
graphic ST segment elevation MI or patients with chronic 
myocardial ischemia. [ 35 ] The simplest delivery route is 
intravenous delivery. It has the advantage of being nonin-
vasive and is often referred to as one of the safest delivery 
methods. [ 36 ] It is usually done through a peripheral or 
central venous catheter. [ 37 ] However, a high number of 
exposed cells may end up in other organs and only a small 
amount will reach the target area, which reduces the effi -
ciency of this technique. [ 38–40 ] Furthermore, patients with 
occluded arteries usually cannot benefi t from an intrave-
nous injection. Another method is the intramyocardial 
injection. This delivery method consists of the direct injec-
tion of stem cells into the myocardium via a transepicar-
dial or transendocardial injection. It is generally used for 
patients with an ischemic cardiomyopathy. The exact loca-
tion of the infarcted tissue can be identifi ed using echocar-
diography or nuclear imaging. [ 41 ] Transepicardial injection 
is performed using a needle-syringe while directly visual-
izing the heart. [ 42 ] However, the operation is risky due to 
the need for open-heart surgery. [ 43 ] The transendocardial 
approach does not require surgery, but it provides less 
visibility because it is performed in a percutaneous way. [ 44 ] 
Catheters are passed from peripheral vessels into the left 
ventricular cavity. [ 42 ] Electromechanical mapping systems 
can be used to increase visibility during the procedure. 
The drawbacks of both techniques include increased risks 
of perforation, embolization and cardiac arrhythmias. [ 45 ] 
The retrograde coronary sinus delivery consists of placing 
a balloon infusion catheter after catheter placement into 
the coronary sinus. The balloon is then infl ated and cells 
are delivered at pressures of 50–60 mm Hg maximum, 
which are higher than the coronary sinus pressure. [ 46 ] This 
emerging technique may be effi cacious and is considered 
safe. [ 47 ] Recent studies have shown that injection using this 
method delivers cells with a better homogeneity across the 
heart. [ 48 ] The last injection method is the intrapericardial 
injection. One of its advantages is a relatively high number 
of deposited cells. However, the movement of cells across 
the visceral pericardium is essential. Little is known about 
the effi ciency of this technique, as it is the least researched. 
To date, there is no specifi c route that has been proclaimed 
to be the fi nest technique for cellular therapy. Table  1 
summarizes the prospects and challenges of different cell 
delivery strategies to maximize the stem cell based thera-
peutic strategies for cardiac tissue repair and regeneration. 
 3.  Mode of Therapeutic Actions: Knowledge 
So Far 
 There have been several studies that show positive remod-
eling of damaged myocardium after stem cell therapy. 
However, some ambiguity still remains on the mecha-
nisms of engraftment of stem cells and their subsequent 
benefi cial effects to the ischemic cardiac zone. The original 
theory that scientists proposed was that the stem cells 
delivered to the myocardium differentiate into new cardi-
omyocytes to produce the positive remodeling of the dam-
aged tissue. However, due to scientifi c evidence that will 
be discussed in the following section, several scientists 
now believe that paracrine signaling between the deliv-
ered stem cells and resident stem cells are responsible for 
those effects. 
 3.1.  Paracrine Signaling 
 Extracellular growth factors, cytokines and ligands con-
stitute parts of signaling pathways at the center of cardio-
myocyte differentiation, development, growth, function 
and metabolism. Low engrafted cell survival and prolifera-
tion with a relatively high outcome in regeneration sug-
gests the involvement of paracrine factors secreted by the 
implanted cells. Stem cell homing factors such as growth 
factors, chemokines and cytokines are believed to improve 
cardiac function through neovascularization, angiogenesis, 
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decreased apoptosis, decreased fi brosis, increased cell pro-
liferation, as well as stem cell mobilization, differentiation 
and migration to the infarct zone. Signifi cant effort is being 
put toward both understanding the mechanisms by which 
these biological molecules produce these positive results 
as well as delivering these molecules using different tech-
niques. These investigations are indicating that these bio-
logical molecules could potentially be used in regenerative 
medicine and tissue engineering to aid stem cells grafting 
and retention in the heart. 
Macromol. Biosci. 2016,  16,  958−977
 Table 1.  Advantages and drawbacks of different types of stem cells, delivery methods and fabricated biomaterials used. 
Stem cell type Advantages Drawbacks Ref.
 Embryonic Clonality, self-renewal, 
pluripotency
Ethical concern  [ 3,10,12,32 ] 
Very sensitive to tempera-
ture and pH changes
 Bone marrow derived adult 
stem cells 
No ethical issues; widely 
investigated under 
pre-clinical and clinical 
settings
Access requires invasive 
surgery
 [ 139 ] 
Isolation is required due 
to heterogeneous cell 
population
 Adipose derived adult stem 
cells 
Less invasive and painful 
surgery
Isolation is required due 
to heterogeneous cell 
population
 [ 3,19,139 ] 
 Induced pluripotent Alternative to embryonic 
cells
Probability of forming 
teratoma
 [ 5,25 ] 
Availability of producing 
large amounts of 
patient-specifi c cells
 Endothelial progenitor Production of large 
amounts of growth factors 
and cytokines
Rare population  [ 31,140 ] 
Delivery methods Advantages Drawbacks Ref.
 Intracoronary No risk of systemic 
delivery
Low cell delivery  [ 35 ] 
Direct delivery
 Intravenous Not invasive Cells can be isolated in 
lung, liver or spleen
 [ 36,38,141 ] 
 Intramyocardial Direct delivery Perforation risk  [ 43 ] 
 Intrapericardial Large number of cells 
delivered
Visceral pericardium trans-
migration required
 [ 40 ] 
 Retrograde coronary sinus Homogeneous cell delivery Endothelial wall transmi-
gration required
 [ 48 ] 
Biomaterials Advantages Possible concerns Ref.
 Cell sheets Long-term survival 
and growth rate after 
implementation
Retention of implant at 
transplant site; integration 
to host tissue
 [ 79,81 ] 
 Injectable hydrogels Enhance stem cell reten-
tion and survivability upon 
injection
Suitable rheological 
properties of the injected 
materials
 [ 142 ] 
 Porous scaffolds Increased Vascularization Biodegradation properties  [ 92 ] 
Engineered Biomaterials to Enhance Stem Cell-Based Cardiac Tissue Engineering and Therapy
 
www.MaterialsViews.com 963© 2016  WILEY-VCH Verlag GmbH &  Co.  KGaA, Weinheim
Macromolecular
Bioscience
www.mbs-journal.de
 Cytokines play an important role in cell differentiation, 
proliferation and apoptosis. They constitute a wide range 
of proteins that are involved in the communication and 
interactions between cells. Tumor necrosis factor-alpha 
(TNF-α) and interleukin-6 (IL-6) are cytokines that are 
released shortly after acute MI. [ 31 ] The sustained presence 
of cytokines leads to the modifi cation in myocyte pheno-
type and activation of matrix metalloproteinases, which 
modifi es the interstitial matrix and further augments 
the remodeling processes. [ 31 ] Cytokines have the ability 
to trigger not only benefi cial pathways to cellular regen-
eration such as restoration of function and angiogenesis, 
but also detrimental pathways such as apoptosis, chronic 
dilatation and stroke. [ 49 ] Chemokines are chemotactic 
cytokines that play an important role in several processes, 
including angiogenesis. [ 50,51 ] A stem cell homing factor that 
has recently received considerable attention is the stromal-
derived factor (SDF)-1-α. [ 52 ] This chemokine has been 
shown to increase transcoronary migration and homing of 
stem cells to the ischemic myocardium, [ 53,54 ] angiogenesis, 
cell survival, [ 52,55 ] and improve ventricular function. [ 56 ] 
Recent research has shown that these positive results are 
due to the local release of SDF-1-α by MSCs that leads to 
the recruitment of CXCR4+ cardiac progenitor cells. [ 57 ] 
Upon the SDF-1-α:CXCR4 binding an antiapoptotic effect 
mediated by the phosphoinositide 3-kinase/Akt sign-
aling pathway was shown. Lastly, the signaling associated 
with this pathway was shown to not cause cardiomyo-
cyte hypertrophy, therefore, eliminating hypertrophy as a 
cause of positive cardiac remodeling. 
 In order to increase the effi cacy of these paracrine 
factors and to take advantage of other delivery routes, 
scientists have recently explored delivery systems such 
as microparticles. [ 58,59 ] These microparticles overcome 
several drawbacks associated with direct injection of 
the paracrine factors including protein instability and 
short circulation protein half-life after injection. Spe-
cifi cally, the PLGA microparticles used by Formiga et al. 
were shown to provide sustained delivery of VEGF 165 for 
more than one month and to increase angiogenesis and 
arteriogenesis. On the other hand, the VEGF solution and 
empty microparticles did not show these results after one 
month. Using particles to increase the clinical viability of 
paracrine factors shows great potential for cardiac regen-
eration. However, degradation, size, protein half-life, 
and release kinetics are all important factors that need 
to be carefully considered when deciding on a delivery 
technique. 
 Although researchers have some cues for reaching 
effective stem cell therapies for the regeneration of the 
heart, there are still many unknown mechanisms that are 
currently under investigation. Concentration on the syn-
ergistic effects of growth factors, cytokines and adequate 
stem cells reveal complex questions but promising results. 
 3.2.  Differentiation of Stem Cells 
 Several scientists are studying ways to differentiate stem 
cells into cardiomyocytes. Successful methods are char-
acterized by the expression of the correct genetic foot-
prints and prevention of tumor cell development. Various 
techniques are being developed to ensure that the correct 
genetic footprint is maintained. One example is seeding 
the cells on scaffolds, which is expected to prevent the loss 
of genetic markers of differentiated cardiomyocytes espe-
cially after implantation into the host cardiac tissue. [ 60 ] 
Furthermore, it is important that the developed methods 
be scalable to allow the transition from experimental to 
clinical applications. [ 61 ] 
 One source of stem cells that has shown capability to 
be differentiated into cardiac muscle lineages is bone 
marrow. [ 62 ] Bone marrow stem cells have been applied 
to various applications such as cardiac patch tissue 
engineering. [ 20 ] According to Fukuda et al., mouse bone-
marrow stem cells differentiated into a cardiac cell line 
demonstrate cardiomyocyte genes. In addition, sponta-
neous beating and pacemaker characteristics that mimic 
native ventricular-myocyte and sinus-node functions 
have also been noted. Nevertheless, this cell source also 
presents some challenges, such as the tendency to dif-
ferentiate into bone and cartilage cells. Another signifi -
cant problem seen with this cell line is that the delivered 
action potentials have smaller values than those found in 
native human myocardium. 
 Several factors have been found to affect the differenti-
ation of stem cells into cardiomyocytes. The source of the 
stem cells greatly affects the lineage they will differen-
tiate into, as revealed by Tompkins et al. through their dis-
cussion on stem cell “memories”. [ 60 ] For example, human 
cardiomyocytes differentiated from cardiac derived iPSCs 
were more easily obtained than those differentiated from 
fi broblast derived iPSCs. Scientists have also found success 
deriving cardiac cells from bone marrow derived MSCs. [ 63 ] 
Another factor that can also affect the differentiation of 
stem cells from various sources into cardiomyocytes is 
the addition of external molecules. Inhibitors can also be 
used to promote differentiation into cardiac cell lineage. 
For instance, the inhibitor trichostatin A has been shown 
to promote embryonic stem cell differentiation into car-
diomyocytes and to increase the physical maturation of 
these cells. [ 60 ] 
 However, the differentiation of stem cells into car-
diomyocytes has also resulted in teratoma development. 
The source of the developed cancer cells is mainly the 
stem cells that remain in their undifferentiated state 
in the culture. Several methods have been proposed to 
remove undifferentiated stem cells and prevent cancer 
cell growth in the differentiated cardiomyocytes. [ 64 ] 
Differentiated cardiomyocytes can be identifi ed and 
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separated from undifferentiated stem cells or those that 
have differentiated into other lineages by fl ow cytom-
etry, micro-dissection, genetic selection, and buoyancy 
measurements. [ 60 ] However, some of these strategies 
themselves induce mutations and teratomas in the cell 
cultures. Therefore, future work needs to be done on how 
to negate this teratoma formation in order for stem cell 
therapy to become a viable widespread treatment option. 
 4.  Boosting Stem Cell Therapy with 
Engineered Biomaterials 
 Different methodologies have been used to deliver stem 
cells to damaged myocardium including cell sheets, inject-
able hydrogels, porous scaffolds, cell-surface engineering, 
and microcapsules. Both natural and synthetic polymers 
have been used to make such delivery devices with each 
type of material providing its own benefi ts and challenges. 
This section will focus on the current research reported 
using each of these methods. Also, the current challenges 
of each method will be discussed along with strategies sci-
entists are using to overcome these challenges to produce 
the best therapeutic benefi t. 
 Natural polymers have several properties that make 
them ideal for tissue engineering and regenerative medi-
cine. One of the most notable and unique characteristics 
is their bioactivity through providing signals to cells. 
Examples of natural polymers used in cardiac tissue 
engineering are collagen, [ 65 ] gelatin, [ 66 ] hyaluronan, [ 67 ] 
fi brin, [ 68 ] chitosan, [ 69 ] alginate [ 70 ] and Matrigel. [ 71 ] Fibrin, 
collagen I, and Matrigel, are commercially purchased 
polymers that can be used as hydrogels in cardiac patch 
tissue engineering with results showing improved car-
diac function as well as increased vascularization of the 
grafted tissues. [ 72 ] One study discovered that human ESCs 
seeded on fi brin-based matrices formed highly function-
alized cardiac tissues and improved results were seen in 
3D gels compared to 2D gels. The properties compared 
were sarcomere length and presence of certain genes for 
cardiac contractility. [ 73 ] Natural polymers can also be used 
for an electrospun scaffold, as seen when a hemoglobin/
gelatin/fi brinogen (Hb/gel/fi b) nanofi berous construct 
was used to study MSC differentiation into cardiomyo-
cytes. [ 74 ] Immunocytochemical assays for cardiac marker 
protein actinin showed that the MSCs did indeed begin 
to differentiate toward a cardiomyocyte lineage. The cells 
also began to exhibit morphological characteristics indic-
ative of cardiomyocytes. However, in general, natural 
polymers suffer from poor mechanical properties and are 
prone to generating immune response from the host. [ 75 ] 
Nevertheless, if these mechanical problems can be over-
come, the bioactivity of the natural polymers can prove to 
be a valuable tool in controlling stem cell behavior. 
 Alternatively, synthetic polymers are attractive because 
of the substantial control scientists have over tailoring 
their physical and chemical properties. Several hydrogels 
are currently being developed to mimic cardiac tissue 
properties and characteristics. [ 76 ] Elastomeric hydrogels, 
for example, have high elastic and tensile strength prop-
erties, which are needed in the tough myocardial environ-
ment. [ 77 ] Enhanced biomimetic properties are also seen in 
conductive hydrogels. These hydrogels have an improved 
ability to conduct electric signals and therefore, assist in 
maintaining a constant synchronization of the beating 
rates for grafted and native cardiac tissues. Scientist have 
also used separate synthetic polymers to create a com-
posite scaffold using two different techniques in order 
to better mimic the native extracellular matrix. [ 78 ] Spe-
cifi cally, Xu et al. used electrospun polyurethane fi bers 
in combination with a hydrogel based on  N -isopropy-
lacrylamide (NIPAAM), acrylic acid (AAc), 2-hydroxyethyl 
methacrylate (HEMA), and oligo (β-butyrolactone). They 
modulated several composition characteristics including 
global moduli, single-fi ber moduli, fi ber alignment and 
density. The bioactivity of these scaffolds was tested by 
electrospraying cardiosphere-derived cells and moni-
toring their differentiation toward cardiomyocytes. The 
results showed that although the cells attached to each 
scaffold composition relatively equally, the RT-PCR car-
diac differentiation was enhanced with the lower scaffold 
modulus and highest fi ber diameter as seen in Figure  1 C. 
This study further confi rms that fi nding the optimal com-
position and mechanical properties of scaffolds is impor-
tant in order for stem cell therapy to reach therapeutic 
effi cacy. Despite the fact that the mechanical properties of 
synthetic hydrogels can be relatively easy to tailor, their 
lack of bioactivity has proven to be a signifi cant problem 
that scientists are continuing to work toward overcoming. 
 4.1.  Cell Sheets 
 The “Cell Sheet Engineering” approach to tissue engi-
neering utilizes stacks of many individually harvested thin 
tissue layers to fabricate an integrated functional tissue 
in vitro. [ 79 ] In its early stages, this approach presented a 
“backward” technique due to the enzymatic harvesting 
steps that destroyed the engineered cells. [ 80 ] However, 
recent advances in scaffold coating strategies have allowed 
the easy detachment of cultured tissues from their “smart” 
scaffolds, keeping any developed cell-surface proteins and 
extracellular matrix connections intact. [ 80 ] The resulting 
stacked cell sheets resemble dense native cardiac tissue, 
and can be implanted without sutures through open 
heart surgery resulting in long-term survival and growth 
rate. [ 79,81 ] As a result, the cell sheet approach has become 
one of the most promising techniques in cardiac tissue 
engineering. [ 82 ] In fact, transplants of stacked cell sheets 
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prepared from skeletal myoblasts into infarcted myocar-
dium in MI rat models have shown positive results con-
cerning vascularization and proliferation of healthy cardiac 
cells in the damaged areas. [ 83 ] Cell sheets derived from 
muscle stem cells have also been shown to yield better 
functional recovery in chronic infarcted myocardium than 
cell injections have. [ 84 ] As shown in Figure  1 A, the cell 
sheets had a signifi cant increase in cell survival, which 
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 Figure 1.  Biomaterial-based approaches for improved cardiac stem cell therapy. A) MDSC sheet formed using temperature-responsive 
polymer (poly( N -isopropylacrylamide). [ 84 ] (i) Cell sheet containing MDSCs transduced with LacZ. (ii) Quantifi cation of live LacZ-positive 12 
weeks after implantation. ( * p < 0.05 vs control,  # p < 0.05 vs injection). (iii) Immunostaining of infarcted area for fsMHC-positive (green) in 
close proximity to Lac-Z-transduced MDSCs (white arrows) 12 weeks after implantation of MDSC sheet to show skeletal muscle-like for-
mation. Scale bar: 50 μm. B)  N -isopropylacrylamide,  N -acryloxysuccinimide, acrylic acid, and poly (trimethylene carbonate)-hydroxyethyl 
methacrylate injectable thermosensitive hydrogel synthesized to improve MSC differentiation to cardiac cells. [ 89 ] (i) Image of hydrogel solu-
tion at 4 °C (top) and solid gel at 37 °C (bottom). (ii) Stress–strain curve for hydrogels with different concentrations of the three polymers. 
(iii) Cardiac gene cnT1 expression for MSCs affected by hydrogel moduli on hydrogels with varying concentration of the three polymers. 
(10% = 16 kPa, 20% = 45 kPa, and 40% = 65 kPa) ( p < 0.05). C) Effect of NIPAAM/AAc/HEMA-oHB6 hydrogel and electrospun polyurethane 
fi ber scaffold on cardiosphere-derived cell differentiation. [ 78 ] (i) Scaffold parameters for each of the four test groups. (ii) SEM image of each 
scaffold. (ii) cTnI expression (green) of CDCs in tissue constructs after 7 d of culture. Cell nuclei were stained by Hoechst (blue). Abbrevia-
tions: fsMHC, fast-skeletal myosin heavy chain; cnT1, cardiac troponin I; MDSC, muscle-derived stem cell; MSC, mesenchymal stem cell; VEGF, 
vascular endothelial growth factor; fsMDSC, fast skeletal myosin heavy chain; SEM, scanning electron microscopy.
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then translated into a better therapeutic outcome in the 
form of reduced scar fractional area and increased forma-
tion of fast-skeletal myosin heavy chain positive myofi bers. 
Bursac et al. discusses the high potential of cell sheets 
seeded with adipose derived MSCs, which after implanta-
tion into infarcted myocardium in rat models increases the 
myocardium wall thickness. [ 83 ] 
 Scientists use thermoresponsive coatings for the 
growing scaffold, which results in the successful growth 
of cardiac tissue in vitro for several reasons. First, each 
cardiomyocyte sheet consists of electrically and chemi-
cally coupled cells and can therefore maintain a syn-
chronized pulsation. [ 81 ] In addition, although cell sheets 
initially lose pulsation after being stacked, synchro-
nized beating is eventually restored and can be seen in 
macroscopic view. [ 81 ] Finally, the engineered graft area 
increases with host size after implantation, accompa-
nied by an increase in conduction velocity and force. 
This is seen in implants of stacked myocardial layers in 
rats over a period of 24 weeks. [ 79 ] The most common ther-
moresponsive material used in the tissue engineering of 
cell sheets is poly( N -isopropylacrylamide) (PNIPAAm), 
which has a low critical solution temperature (LCST) of 
32 °C. [ 80 ] This implies that the polymer is hydrophobic 
at temperatures above 32 °C, which encourages cell 
adhesion, and hydrophilic at temperatures below 32 °C, 
which encourages cell detachment. [ 79 ] These charac-
teristics make the polymer ideal for tissue engineering 
applications; cells can be cultured on the PNIPAAm pol-
ymer at their nominal growth temperature of 37 °C and 
then safely harvested at a temperature below the LCST 
without damaging the cell-to-cell junctions or the extra-
cellular matrix found between the harvested cells. [ 82 ] 
Another recent study showed that ASC cell survival in 
an ischemic heart can be increased by using thermore-
sponsive cell sheets. [ 85 ] These cell sheets were shown to 
improve ejection fraction as well as develop a new vas-
cular network. Another example is the use of human 
amniotic fl uid stem cells which have shown positive 
results when seeded on collagen hydrogels coated with 
temperature responsive material, such as methylcellu-
lose hydrogels. [ 86 ] Transplantation of the obtained cell 
sheets increased the left ventricle size in infarcted rat 
models within four weeks. [ 86 ] Improved engraftment 
was also seen due to the increased extracellular matrix 
obtained from the cell sheet method. [ 86 ] 
 4.2.  Injectable Hydrogels 
 Hydrogels are 3D networks of polymers that share sev-
eral characteristics with natural extra-cellular environ-
ments. [ 77 ] They are hydrophilic and swell when exposed to 
water, and they can also promote the growth and adhesion 
of cardiovascular cells. Tissue engineering of cardiac tissue 
based on injectable hydrogels begins with encapsulating 
the cells. [ 87 ] This is achieved by mixing the cells and the 
matrix solution before incubating the solution for gela-
tion. [ 81,87 ] The resulting gel is a homogeneous mixture con-
sisting of cells, extracellular matrix proteins, and polymer. 
The gel is directly injected into the desired host cardiac 
tissue as a liquid and then polymerizes in the host tissue, 
becoming fi xed. [ 81 ] The complete biodegradation of all 
polymer residues has been reported within six weeks after 
injection. Hydrogels have been reported to enhance stem 
cell retention and survival upon their injection into animal 
heart models. [ 88 ] Also, hydrogels provide an environment 
for cells where scientists can control the mechanical prop-
erties and, therefore, enhance stem cell differentiation. Li 
et al. encapsulated MSCs in a thermosensitive hydrogel 
made of  N -isopropylacrylamide,  N -acryloxysuccinimide, 
acrylic acid and poly(trimethylene carbonate)-hydroxye-
thyl methacrylate. [ 89 ] These hydrogels had varying moduli 
due to varying concentrations of the polymers used. The 
results showed that the cells encapsulated in the hydrogel 
with the highest modulus had a greater increase in MSCs 
differentiation to cardiomyocytes as seen in Figure  1 B. 
Hydrogels that have been injected with hESC vascular cells 
show improved vascularization of infarcted heart areas in 
rat models and maintain myocardium contractile rates. [ 90 ] 
This has also been correlated with a decrease in area of the 
damaged site, viewed using magnetic resonance imaging 
techniques. [ 90 ] Due to their relative ease of delivery and 
tunable properties, injectable hydrogels hold a great 
promise for enhancing the effi cacy of stem cell therapy to 
the heart. 
 4.3.  Porous Scaffolds 
 Porous scaffolds are distinguished from hydrogels by 
their interconnected pores that allow the seeded cells to 
travel, proliferate, communicate, and form extracellular 
matrix components throughout the entire scaffold. [ 91 ] 
These pores also permit diffusion of nutrients and met-
abolic wastes. Pores are essential to cardiac tissue scaf-
folds as they increase vascularization, especially when 
combined with medium perfusion techniques that can 
enhance cardiac cell motion through the scaffold. [ 92 ] Scaf-
folds can be made porous through various techniques, 
depending on the material being used and the pore char-
acteristics. [ 93 ] These techniques include freeze drying, [ 94 ] 
leaching, [ 95 ] 3D printing, [ 96 ] electrospinning, [ 97 ] and fi ber 
extrusion. [ 98 ] 
 Scaffolds from natural and synthetic materials can be 
used in cardiac tissue engineering, although some have 
been shown to be more receptive to cardiac cell seeding 
than others. [ 99 ] According to Herrmann et al., polyure-
thane is identifi ed as being among the best in the con-
text of myocardial tissue engineering. [ 99 ] Fromstein et al. 
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revealed the effect of different scaffold architectures on 
the development of cardiac patches from cardiomyocytes 
derived from embryonic stem cells. [ 100 ] Polyurethane 
scaffolds having different “macro-architectures” were 
fabricated using electrospinning or thermally induced 
phase separation (TIPS) techniques. Although both fab-
rication methods resulted in patches with contracting 
cells, only the stem cells seeded on the fi brous meshes 
from the electrospinning technique developed into the 
typical elongated morphology seen in cardiomyocytes 
derived from ESCs. Rai et al. developed a biomimetic PGS 
hydrogel sequentially treated with alkaline hydrolysis 
and acid and reported homogenous immobilization of 
the fi bronectin and laminin peptide sequence. [ 101 ] It was 
shown that the porous PGS scaffold is biocompatible with 
rat CPCs and human cardiac MSCs. These results hold 
promise for PGS to serve as biomaterials for carriers of 
cells into the heart for cardiac tissue engineering. Ravi-
chandran et al. discusses several comparable mechanical 
properties between PGS, fi brinogen core, shell scaffolds 
and native myocardial tissues. [ 102 ] Similarly, Prabhakaran 
et al. studied the embryonic stem cell behavior on a 
poly(d,l-lactide-co-glycolide)/collagen (PLGA/Col) scaffold 
versus a pure PLGA scaffold. [ 103 ] They found that the PLGA 
scaffold exhibited much higher tensile strength prop-
erties. However, the PLGA/Col scaffold proved to better 
support the interaction and growth of ESC differentiated 
cardiomyocytes. This highlights the importance of com-
bining natural and synthetic polymers in the production 
of porous scaffolds in order to obtain a scaffold that can 
facilitate cell adhesion and provides ideal mechanical 
properties for cardiac tissue engineering. [ 93 ] 
 4.4.  Cell-Surface Engineering with Bioactive Molecules 
 As mentioned previously, stem cells have the potential to 
regenerate tissue damaged by several cardiovascular dis-
eases including myocardial infarction. However, to date, 
cell therapy has not reached the effi cacy level needed and 
requires invasive surgeries to deliver cells to the target 
location. Ideally, a systemic infusion should be used, but 
only approximately 1% of the cells have been shown to 
home to the tissue of interest. [ 104 ] In addition, regardless of 
which delivery technique is used, scientists have observed 
that less than 10% of the injected stem cells are present 
in the heart 24 h following treatment. [ 105,106 ] Therefore, 
scientists have begun modifying the surface of stem cells 
in order to promote cell homing and engraftment at the 
treatment site. This can be accomplished by stimulating 
interactions between the stem cells and the endothelium 
typically used by hematopoietic stem cells and leukocytes 
that MSCs inherently lack. [ 104,107,108 ] These interactions 
lead to initial rolling and subsequent adhesion that results 
in transendothelial migration into the tissue. Specifi cally, 
Sarkar et al. used glycoprotein ligand-1 of the P-selectin 
active site called sialyl Lewis X (SLeX). [ 104 ] They attached 
a SLeX to MSCs using a biotin–streptavidin bridge after 
a lipid vesicle had been attached to the cell membrane 
using biontinylation. A schematic representation of the 
synthesis can be seen in Figure  2 A. Their results showed 
that under shear stress the modifi ed cells had a greater 
percentage of cells interacting with a P-selectin coated 
surface through both adhesion and rolling mechanisms. 
Although this method proved to be effective, streptavidin 
may cause an immune response and a method with less 
steps is more ideal. Cheng et al. used a simple procedure 
to chemically modifi ed the MSC membrane using NHS-
PEG 2 -maleimide as a membrane bound linker molecule 
and cysteine to provide the  N -terminus thiol needed to 
react with maleimide. [ 107 ] After attaching a known strong 
binding peptide to the MSCs using this method it was 
shown that the cells targeted and adhered to E-selectin 
in an in vitro model of an infl amed blood vessel under 
physiological shear stress. In addition, this group proved 
that the binding kinetics of the peptide–selectin interac-
tion can be modifi ed in order to promote the MSCs to roll 
under physiological shear stress. To accomplish this they 
used a peptide that had a moderate binding IC50 with 
E-selectin to modify the stem cell membrane. This dis-
covery is particularly important for the fi eld because it 
validates theoretical models that had previously only been 
used to explain natural cell or bead rolling. This allows 
scientists in the future to refi ne theoretical models in 
order to develop better engineered cells for the purpose 
of targeting damaged tissue like damaged myocardium. 
It is important to note that both studies confi rmed inter-
actions were observed while the MSCs maintained their 
viability, proliferation, and differentiation ability. These 
studies prove that by modifying the surface of stem cells 
in accordance with specifi c ligands expressed by the target 
cell type, scientists have the ability to promote inter actions 
leading to stem cell homing after systemic injection and 
increased retention regardless of which delivery route is 
chosen. Targeting the specifi ed adhesion molecules men-
tioned above holds great promise for tissue regeneration 
due to the fact that both E and P-selections are overex-
pressed by infl ammatory cytokine-activated endothelial 
cells present in damaged tissue including damaged myo-
cardium. Recently, Chi et al. reported a pilot study in which 
they tested this theory using a porcine ischemia-reper-
fusion model. [ 105 ] Results showed that by incorporating a 
P-selectin glycoprotein ligand-1 mimetic onto the surface 
of cardiosphere-derived cells they were able to detect 28% 
of the cell population in the left anterior descending coro-
nary artery region 3 h after injection. Although this study 
confi rms the feasibility of using selectin-ligand function-
alized cardiosphere-derived cells for targeted regeneration 
of damaged myocardium, future tests should be aimed at 
Macromol. Biosci. 2016,  16,  958−977
A. Hasan et al.
 
www.MaterialsViews.com968 © 2016  WILEY-VCH Verlag GmbH &  Co.  KGaA, Weinheim
Macromolecular
Bioscience
www.mbs-journal.de
investigating the retention of the cells in the target region 
at longer time points in larger in vivo studies. 
 4.5.  Polymeric Microcapsules 
 Although stem cell injections directly into the myocardium 
have been shown to promote positive remodeling of the 
tissue, the problem of cell retention still remains. Once 
injected, scientists have found that the contractile nature 
of the myocardium fl ushes the stem cells away from the 
site. [ 109 ] One method being studied in order to overcome 
these problems is the use of microcapsules as delivery 
systems for stem cells. As mentioned with the previous 
methods, a major benefi t of using a polymeric delivery 
method such as microcapsules is that the mechanical 
and biological properties of the microcapsules can be 
manipulated based on polymer composition to infl uence 
stem cell behavior. However, due to the relatively small 
size of microcapsules, there are rarely concerns regarding 
adequate transport of oxygen and nutrient to the cells 
that other hydrogel techniques might encounter. [ 110 ] Sev-
eral polymers have been used for such microcapsules, 
including extracellular matrix proteins, [ 111 ] PLGA, [ 112 ] 
alginate, [ 113 ] fi brinogen, [ 114 ] and chitosan [ 115 ] among sev-
eral others. Specifi cally, Paul et al. recently used alginate 
microcapsules to encapsulate genetically modifi ed human 
adipose-derived stem cells. [ 113 ] They used recombinant 
baculovirus and PAMAM dendrimers to transduce the 
cells with a gene to cause the overexpression of VEGF. As 
reported in Figure  2 B, due to this overexpression of VEGF 
when the cells were injected into a rat model, signifi cant 
positive remodeling was observed over a 10 week period 
in the form of increased injection fraction, fractional short-
ening, angiogenesis and arteriogenesis. Recently, Blocki 
et al. developed a composite microcapsule for the encap-
sulation and delivery of MSCs to the myocardium post 
myocardial infarction. [ 111 ] The biomaterials used for the 
microcapsule production were agarose, collagen I, fi brin, 
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 Figure 2.  Biomaterial-based delivery systems for enhanced cardiac stem cell therapy. A) Modifi ed MSCs using biotinylated lipid vesicles for 
systemic cell targeting. [ 104 ] (i) Schematic of vesicle formation and MSC modifi cation. (ii) Effect of shear stress on percentage of cell inter-
actions with the P-selectin coated surface in a fl ow chamber assay at 0.5 dyn cm −2 . B) Microencapsulated stem cells for myocardial infarc-
tion therapy. [ 113 ] (i) hASCs encapsulated in alginate-based microcapsules. Scale bar: 50 μm. (ii, iii) Microencapsulated stem cells, genetically 
modifi ed to express GFP (transduced with only baculovirus or PAMAM dendrimer coated baculovirus), under fl uorescence microscope on 
day 2 post encapsulation. The white circles show the peripheral surface of the microcapsules. Scale bar: 100 μm. (iv) Photograph shows 
direct intramyocardial delivery of microencapsulated hASCs to the peri-infarct sites of rat heart. This strategy results in an improved cell 
retention, rapid angiogenesis, and improved cardiac function. Abbreviations: MSC, mesenchymel stem cell; hASCs, human adipose-derived 
stem cells; PAMAM, polyamidoamine; VEGF, vascular endothelial growth factor; PEG, polyethelene glycol; GFP, green fl uorescent protein.
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and dextran sulfate. The slow degradation profi le of aga-
rose allows for cells to be released into the damaged tissue 
in a controlled manner while the extracellular matrix 
proteins and dextran sulfate were chosen due to their 
ability to positively impact cell behavior. More specifi -
cally, the presence of dextran sulfate caused extensive cell 
spreading, proliferation and survival within the microcap-
sules. Following their material optimization, in vivo tests 
were carried out in a rat model where the microcapsules 
containing MSCs labeled with TAT peptide derivatized 
ultrasmall superparamagnetic iron oxide nanoparticles 
were injected into the peri-infarct and infarct region of the 
heart. A magnetic resonance signal indicating the pres-
ence of labeled MSCs could be detected up to 6 weeks in 
the groups that received the microencapsulated MSCs. 
However, at most, a weak signal was detected early in the 
group that received a single cell suspension. These results 
indicate that the microencapsulation of the MSCs did 
increase the cell retention in the damaged myocardium. 
Future studies assessing cardiac function post treatment 
would be benefi cial in order to fully assess the therapeutic 
benefi t of this treatment. Instead of using some of the 
natural polymers mentioned above, Lee et al. used PLGA 
in combination with polyethylenimine (PEI 1.8k ) in order 
to encapsulate MSCs in porous microcapsules. [ 112 ] PLGA 
was chosen due to its ideal degradation profi le and PEI 1.8k 
was added in order to enhance cellular retention due to 
electrostatic interactions. In vivo results showed that after 
injection into the damaged myocardium all three micro-
encapsulated cell groups had a greater engraftment rate 
2 weeks after treatment. However, as stated previously, 
further in vivo test should be performed in the future to 
assess how the cardiac function is affected by these posi-
tive results. In addition, in vivo testing over a longer time 
period, as seen in the previous examples, is needed to 
make an accurate assessment of the therapeutic potential 
of the treatment. These examples along with other studies 
provide evidence that microcapsules offer scientists with 
a viable method for enhancing stem cell therapy by pro-
viding a tunable delivery system. 
 5.  Role of External Mechanical 
Stimuli on Cardiac Differentiation 
 Stem cells are unique in the fact that they differentiate 
based on the biological and mechanical cues they receive 
from their environment. Scientists have used this trait to 
their advantage by seeding cells on substrates with spe-
cifi c mechanical properties, and also by subjecting the 
cell seeded substrates to mechanical stimulation. For a 
tissue engineering approach, scientists use bioreactors 
as an attempt to improve the engineered cardiac tissue 
by driving it to mimic native cardiac muscle behavior. [ 116 ] 
Subjecting stem cells to biomimetic signals also improves 
cardiac gene expression in differentiated stem cells. 
 When designing a device for stem cell delivery, the 
fabrication method and material properties can greatly 
infl uence the stem cell fate. [ 117 ] This is called mecha-
notransduction, and is when the mechanical properties 
of the material evoke a physical stimulus that translates 
into a biological response in the cells. Scientists have used 
this to their advantage when choosing the materials to 
use for stem cell delivery devices. For example, Williams 
et al. studied how the modulus of hydrogels with different 
compositions of ECM and fi brin affected the behavior of 
C-kit+ progenitor cells. [ 118 ] As seen in Figure  3 A, as the 
moduli of the substrate increased the cardiovascular gene 
expression increased as well. This indicates that stiffer 
substrates provoke this type of progenitor cell to differen-
tiate toward a cardiac lineage. Another example of stem 
cell fate dictated by substrate properties can be seen in 
the study by Sreerekha et al., where scientists observed 
how the diameter of electrospun PLGA and PLGA-fi brin 
fi bers infl uenced MSC behavior. [ 119 ] This study proved 
that a composite scaffold with fi brin nanofi bers ranging 
from 50 to 300 nm and PLGA microfi bers ranging from 
2 to 4 μm enhanced MSC differentiation into cardiomyo-
cytes and proliferation. This provides evidence that a sub-
strate with a heterogeneous network of fi bers provides a 
more ideal environment for cardiomyocytes to thrive. 
 Another method for infl uencing stem cell fate is sub-
jecting the cells to mechanical stimulation using a bio-
reactor. The fi rst type of bioreactor was used to mimic the 
physical and mechanical stimulations found in the envi-
ronment of native cardiac muscles. [ 120 ] This conditioning 
increases the force of contraction generated in rat cardiac 
constructs revealing the importance of mechanical biore-
actors in engineering biomimetic cardiac muscles. [ 116,121 ] 
Mechanical simulation of engineered cardiac tissues has 
also been shown to enhance cardiomyocyte prolifera-
tion. [ 121 ] In fact, elastic properties have been improved by 
seeding mouse embryonic stem cells onto poly(lactide-co-
caprolactone) scaffolds and stimulating the scaffold using 
cyclic stretch bioreactors. [ 90 ] Guo et al. demonstrated that 
stretching cardiac patches fabricated from differentiated 
ESCs also results in synchronous beating and response to 
environmental changes. [ 122 ] Proper stimulation of stem 
cells is a vital step in the development of cardiac patches 
because their differentiation into a certain cell line is 
determined by the signals they are subjected to. [ 83 ] For 
example, imposing a 2 Hz cyclic stretch over a period of 
7 d was shown to prevent tumor development in cardiac 
patches developed from embryonic stem cells. [ 83 ] Another 
example was shown by observing the effect of static 
strain on a MSC seeded electrospun poly(ester carbonate 
urethane) scaffold. [ 123 ] The electrospinning technique 
allowed scientists to fabricate a scaffold that mimicked 
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the anisotropic and biaxial mechanical properties of 
native porcine myocardium. As shown in Figure  3 B, the 
magnitude of static strain greatly affected both the cell 
morphology and differentiation. The anisotropic index 
of the tissue construct without static stain was 0.14. 
However, after applying a 75% static strain the aniso-
tropic index changed to 3.28 and the difference in cel-
lular alignment can clearly be visualized in the Figure. 
Even more intriguing is the dramatic upregulation of key 
early cardiac differentiation genes GATA4 and Nkx2.5 
that was detected. When compared to the MSCs cul-
tured on standard tissue plates, the 75% strained tissue 
constructs exhibited approximately a 4000 and 600 fold 
increase of GATA4 and Nkx2.5 expression, respectively. 
These results clearly demonstrate the immense poten-
tial of using mechanical stimulation to engineer a tissue 
construct that mimics both the mechanical and cellular 
properties of the myocardium. Current bioreactors are 
sophisticated, large, unreliable, and diffi cult to operate 
and maintain. [ 121 ] This prevents their use in the mass-
production of cardiac patches and limits them to experi-
mental applications. Nevertheless, recent advances in 
bioreactor technologies have allowed the recreation of 
the native cardiac environment in the lab by providing 
the needed mechanical, biochemical and electrical sig-
nals. [ 9 ] In addition, the emergence of several prototypes 
for portable micro-bioreactors [ 124 ] with minimal pumps, 
valves, and accessories [ 125 ] improves the potential of 
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 Figure 3.  Mechanobiology to control stem cell. A) Characterization of ECM-fi brin gels with varying concentrations of TG. [ 101 ] (i) Young’s 
modulus of gels produced by uniaxial testing. (ii) Swelling ratio. (iii) Cardiovascular gene expression of smooth muscle marker CNN1 and 
endothelial in gels with either neonatal ECM or adult ECM 21 d after cardiac progenitor cell seeding. B) (i) Anistroic fi ber morphology shown 
in 2000× SEM micrograph of poly(ester carbonate urethane) electrospun scaffold. [ 123 ] (ii, iii) Z-stack confocal images of tissue constructs at 
different strains (0% and 75%). Rhodamine phalloidin was used to stain F-actins of the cells. Scale bar: 20 μm (iv, v) Real time RT-PCR analysis 
of cardiac specifi c genes GATA4 and Nkx 2.5. Control group represents the gene expression of MSCs culture on tissue culture plates. Control 
group values were used for normalization. Abbreviations: SEM, scanning electron microscopy; RT-PCR, reverse transcription polymerase 
chain reaction; TG, transglutaminase; ECM, extracellular matrix; CNN1, calponin 1.
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tissue engineering to eventually meet the clinical need 
and mass production of cardiac patches. [ 126 ] Biochemical 
stimulation can also be used. Bioreactors within this cat-
egory are denoted by “spatial control” reactors, since they 
are used to deliver growth factors and molecules in spe-
cifi c amounts within the required cells only. [ 127 ] Biochem-
ical stimulation enhances the vascularization of cardiac 
patches engineered from rat models, which increases the 
amount of oxygen supplied to the cardiomyocytes to the 
required level found in native tissues. [ 116 ] 
 Lastly, cardiac patches are subjected to electrical bio-
reactors. Electrical stimulation of engineered cardiac 
tissue aligns cardiomyocytes seeded onto scaffolds. [ 121 ] 
In addition, it enhances the electrical conductivity 
properties of the engineered cardiac muscle by increasing 
the electrical coupling between the cells, which increases 
the conduction velocity and establishes a rate comparable 
to that of native cardiac tissues. [ 121 ] This has been shown 
through several experiments performed on rat and mouse 
cardiac patch models which highlights the ability to engi-
neer “pacemaker” cardiomyocytes. [ 9,121 ] 
 Cyclic stretching, stretching, Percoll gradient centrifu-
gation, and electric fi eld stimulation are some of the 
common bioreactors and stimulation techniques used 
in preparing cardiac patches from various stem cell 
sources. [ 83,122 ] These techniques can also be helpful in 
stem cell proliferation and expansion in vitro. [ 122 ] Some 
of the most important types of bioreactors are outlined 
in Table  2 , along with their potential applications and 
benefi ts. Although there are signifi cant obstacles asso-
ciated with the use of bioreactors as mentioned above, 
this technology provides a valuable tool for scientists to 
engineer more sophisticated cardiac patches in vitro prior 
to implantation. This has the potential for these types 
of devices to have a reduced risk of failure when trans-
planted into the human body. 
 6.  Implementing Microscale Techniques 
for Cardiac Tissue Engineering 
 Cardiac cell engraftment and retention has remained 
variably low after transplantation of tissue constructs 
into the heart. One main reason is the insuffi cient fl ow 
of oxygen and nutrients that is required through an intri-
cate micro-vessel network. The formation of this network 
is currently slow, resulting in dying cells because of the 
lack of blood vessels in the proximity. Microfl uidics offers 
some remedies for this problem in the area of tissue engi-
neering by enabling scientists to control the spatial dis-
tribution of cells and the chemical gradients. Scientists 
can also induce fl ow signaling and transduction, thereby 
achieving high precision in the reproduction of the car-
diac in vivo microenvironment. [ 128 ] This section will focus 
on different methods in which scientists are creating 
vascular networks using microfl uidics for cardiac tissue 
engineering. 
 In cardiac tissue engineering, vascularization is a cru-
cial element for cell survival and improvement of car-
diac function. Prevascularization and angiogenesis/vas-
culogenesis are two methods that are used to construct 
vessel networks. Prevascularization aims at constructing 
branched perfusable blood vessel networks in the car-
diac cell tissue prior to implantation. The vessel network 
is designed such that anastomosis occurs instantly upon 
implantation. With this prevascularization technique 
researchers have gained a precise control over the spa-
tial arrangement of the vessel network. Microfl uidics 
offers a number of techniques for the in vitro forma-
tion of vessel networks which can be grouped under
(1) subtractive methods (needle-based molding method 
or dissolvable network-based sacrifi cial molding [ 129 ] ),
(2) additive methods (bonding of preformed hydrogel 
slabs) and (3) hybrid methods (bioprinting). [ 130 ] Con-
tinuous delivery of oxygen and nutrients, continuous 
removal of metabolic wastes, high rate of vascular anas-
tomosis, immediate perfusion, and maturation upon 
implantation are major advantages of prevasculariza-
tion. In vasculogenesis and angiogenesis, the scaffold 
is prepared in vitro using techniques that enhance 
blood vessel formation in vivo. Preparation techniques 
for vessel formation using microfl uidics technologies 
include (1) micropatterning, (2) use of functionalized bio-
materials, (3) induction of gradient of growth factors and
(4) control of cell to cell interactions using co-culture of 
multiple cell types. [ 129,130 ] Micropatterning can also be 
used to guide the proliferation and alignment of stem 
cells in order to create a more functional tissue. [ 131 ] For 
example, Giridharan et al. cultured embryonic cardiomyo-
blasts on a thin poly-dimethyl-siloxane (PDMS) synthetic 
polymer membrane in a device modeling the left ventricle 
resulting in a construct that succeeded in simulating 
diastolic loading. [ 132 ] Tsang et al. proved this concept by 
using methacrylated gelatin to create a micropatterned 
hydrogel and subsequently seeded the construct with 
cardiomyocytes. [ 131 ] As seen in Figure  4 A, this micropat-
terning produced cells with more regular beating char-
acteristics, which is a quality that cardiomyocytes need 
to up hold in order for the heart to function properly. 
Along with micropatterning, microwells have also been 
shown to control the fate of stem cells due to the cells 
growing a spheroid bodies instead of in sheets. Recently, 
Yu-Shik et al. discovered that the size of the wells and, 
therefore, the size of the cell body grown infl uence which 
cell lineage stem cells differentiate into. [ 133 ] They used 
embryonic bodies for their study and found that the 
larger the cell bodies exhibited cardiogenesis (Figure  4 B) 
and the smaller cell bodies differentiated to an endothe-
lial cell lineage. Another study compared the maturity of 
Macromol. Biosci. 2016,  16,  958−977
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cardiomyocytes differentiated from human pluripotent 
stem cells (hPSCs) cultures in 2D sheets and 3D cardio-
spheres. [ 134 ] As seen in the images of Figure  4 C, the hPSCs 
that were grown as aggregates showed a signifi cant 
increase in cardiomyocyte characteristics. Specifi cally, 
the cell aggregates produced more homogenous popula-
tion of cardiomyocytes with better intracellular calcium 
transients and contractility. These studies provide further 
evidence that stem cell differentiation can be infl uenced 
by several environmental factors that scientists can use 
to their benefi t for specifi c regenerative purposes. 
 Biomaterials strongly determine the limitations of these 
technologies. [ 145 ] Starting with silicon etching, microfl u-
idic cardiac tissue engineering later evolved to use PDMS 
Macromol. Biosci. 2016,  16,  958−977
 Table 2.  Different types of bioreactors for cardiac tissue engineering. 
Bioreactors Culture type Advantages Examples Ref.
 Perfusion Scaffolds Enhances mass transfer of oxygen 
through the engineered patch
Vascular cells reveal changes 
in their metabolic and 
functional properties after 
exposure to increased levels 
of shear stress, as well as 
increased cell distribution and 
lower diffusion gradients
 [ 120,143 ] 
Creates frictional shear stress 
on the cells which enhances cell 
proliferation
 Multi-shear 
perfusion 
Scaffolds Delivers different shear stresses at 
the same time
DNA content of cultured cells 
increases by 91% after expo-
sure to the bioreactor
 [ 120 ] 
Can be used on 3D tissues
 Pulsatile fl ow Cell-Sheets Enhances vascularization of stacked 
cell sheets
Stacking of six layers of rat 
cardiac cell sheets resulted in 
a thicker and denser grafts, 
which contracts regularly after 
implantation into host rat
 [ 120 ] 
 Uniaxial cyclic 
stress 
Scaffolds Increases cardiomyocyte size Human cardiac constructs 
implanted into rats after expo-
sure to uniaxial loading dis-
played increased active force 
and enhanced graft perfusion 
into host tissue
 [ 120 ] 
Aligns fi bers in the ECM
Increases angiogenesis
 Rotational wall 
vessel 
Cell-culture 
vessels
Creates laminar fl uid fl ow Cardiomyocytes cultured in 
these bioreactors have a con-
stant pH, %CO 2 , and %O 2 , com-
pared to an increasing amount 
of DNA in the culture.
 [ 143 ] 
Enhances mass transfer rate
 Electrical 
stimulation 
Scaffolds and 
hydrogels
Ensures impulse propagation Cardiac constructs propagate 
continuous pulses and a 
rate of 400 beats min −1 after 
inserting in an electrical 
stimulation bioreactor
 [ 144 ] 
Increased conduction velocities to 
mimic in vitro conditions
Caused synchronous macroscopic 
pulses
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scaffolds, which ensure high fi delity and high feature 
resolution but offer only low cell attachment. Annabi 
et al. devised a method to coat the PDMS channel walls 
with tropoelastin-based hydrogel layer and observed an 
increase in cell attachment. [ 135 ] Increase in cell attach-
ment levels led them to anticipate that the method may be 
useful to produce elastic tissues such as blood vessels. [ 135 ] 
However, since PDMS is not biodegradable, some appli-
cations moved to poly(lactide coglycolide) PLG and poly-
glycerol sebacate (PGS). [ 129 ] PGS is believed by some to be 
superior in properties to PLG, because the latter swells in 
vivo and causes chronic infl ammation while PGS degrades 
slowly mainly due to surface erosion. [ 136 ] An application 
involving PGS with a built-in vascular network showed the 
successful biodegradation of PGS with an infi ltration of 
host cells into the vessel network but without any imme-
diate anastomosis upon implantation. [ 137 ] Hydrogels were 
also introduced into these applications, which provided 
several advantages since they allow large biomolecule and 
gas exchange, remove the 3D constraints on cell interac-
tion, [ 129 ] as well as, facilitate the control over the physical, 
mechanical and biological microenvironments. [ 130 ] 
 The microfl uidic and micropatterning techniques men-
tioned in this section offer a valuable strategy to solve the 
common problem in tissue engineering of inadequate 
vascularization. [ 146,147 ] The spatial control over biomaterials, 
Macromol. Biosci. 2016,  16,  958−977
 Figure 4.  Microscale techniques for controlling stem cell behavior. A) (i) Optical profi lometry of patterned 67% PD gelatin hydrogel. A) (ii) 
Cardiomyocyte beating characteristic of unpatterned and patterned gelatin gels at varying PD concentrations. Pixel intensity was used to 
monitor the gels over a 30 s period  [ 131 ] B) (i, ii) Morphology of beating EBs, immunocytochemical characterization of cardiomyogenic differen-
tiation identifi ed by sarcomeric α-actinin and evaluation of beating EBs cultured in microwells. Inset for 150 μm EB fi gure indicates control 
stained only with secondary antibody. Scale bar: 100 μm. [ 133 ] C) Immunostaining for sarcomeric α-actinin (green) and nuclei (blue) of three 
different pluripotent cell sources harvested from day 21 monolayer cultures and day 7 cardiosphere. [ 138 ] Scale bars: 50 μm. Abbreviations: 
hiPSC, human induced pluripotent stem cell; hESCs, human embryonic stem cell; PD, photodegradable; EB, embryonic bodies.
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cells, and biomolecules provides the opportunity for scien-
tists to engineer a tissue construct with a vasculature net-
work more indicative of native myocardium prior to implan-
tation. This increases the chances for success in the treat-
ment by reducing cell death due to lack of proper oxygen, 
waste, and nutrient transport. Hydrogels are the most 
common biomaterials used today for microfl uidic applica-
tions in cardiac tissue engineering, however, challenges 
still remain in fi nding the biomaterial that is superior in 
all the characteristics needed for microfl uidic devices. Fur-
thermore, although this technology has made great strides, 
concerns still remain in inadequate engraftment of cardiac 
patches after transplantation. Lastly, in order for cardiac 
patches to become clinically viable the thickness of the 
patches must increase while still maintaining the mature 
prevascularization discussed in this section. 
 7.  Conclusion and Future Outlook 
 Research for cardiac tissue engineering and regenerative 
medicine with stem cells is greatly advancing with the 
use of biocompatible materials further increasing their 
therapeutic effi cacy. Accessible sources of stem cells for 
cardiac applications have been located but their survival 
in vivo after specialization has been continuously reported 
to be modest. Several types of stem cells have been iden-
tifi ed: embryonic stem cells which are subject to ethical 
issues, adult stem cells which are diffi cult to locate, extract 
and separate from their heterogeneous environment and 
iPSCs which are easily accessible, expandable, patient spe-
cifi c and have so far proven to have therapeutic potential. 
Moreover, the challenge of translating these cell types into 
a clinical setting in a timely and cost effective manner still 
remains. Studies have shown that combining multi ple cell 
types with growth factors in cardiac therapies generates 
better results, however, there still has not been a specifi c 
combination that has had adequate regenerative capacity 
for clinical translation. In addition, recently the hypothesis 
that paracrine factors are the primary mediators of cardiac 
regeneration by stem cells has gained support among scien-
tists. However, there are still many unknown paracrine and 
differentiation mechanisms regarding stem cell behavior 
in the cardiac microenvironment. Future studies dedi-
cated to understanding these mechanisms would provide 
valuable insight into treatment parameters and designs. 
Choosing the optimal route is crucial for a successful 
treatment, and is done based on the specifi c clinical case. 
Among the available routes for stem cell delivery (intra-
coronary, intravenous, intramyocardial, retrograde coro-
nary sinus and intrapericardial), the predominant delivery 
methods in clinical trials today are intracoronary and intra-
mural route of administration. In tissue engineering, the 
different methodologies that combine cells and materials 
(cell sheets, porous scaffolds, injectable hydrogels, cell sur-
face engineering, and microcapsules) have each succeeded 
in enhancing cardiac repair. Nevertheless, in order to make 
these treatments easier to translate into the clinical setting 
the development of minimally invasive delivery techniques 
will be important. The main issues remain with improving 
the electrical, chemical and biomechanical properties of 
the cardiac construct to match those of the heart as well 
as increase the functionality and speed of formation of the 
vessel network within the construct. Bioreactors, which are 
designed to test the prepared cell cultures by simulating 
the in vivo environment, allow for improvement of the 
construct designs within labs. However, they are still too 
sophisticated to enter mass production. Future studies are 
turned toward understanding the behavior of the cultured 
stem cells in 3D constructs and controlling their environ-
ment through time and space. Recent advances in cardiac 
repair are directed at designing patient-specifi c supports 
for clinical applications. While no generally accepted solu-
tion for stem cell based cardiac therapy has been reached 
yet, the fi eld of research is advancing quickly with more 
promising technology and results. 
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